Gabapentin (Neurontin, Gralise, Horizant) and Black patients
Brand names: Neurontin, Gralise, Horizant
What Gabapentin does
Gabapentin is most commonly used off-label for neuropathic pain, anxiety, and insomnia, despite modest trial evidence for most of these indications. It is FDA-approved for post-herpetic neuralgia and as an adjunct anti-seizure medication.
What the evidence says for Black patients
Gabapentin's rise as a de facto 'non-opioid' pain medication has had complex equity effects for Black patients:
- Pain under-treatment pattern. Gabapentin is increasingly offered when an opioid would be clinically indicated, in order to avoid opioid prescribing. Because Black patients are already at higher risk of opioid under-treatment (Hoffman et al., 2016), the rise of gabapentin-as-substitute can institutionalize under-treatment rather than provide adequate analgesia.
- Modest efficacy. Recent meta-analyses (Moore et al., Cochrane 2017, and others) find gabapentin's efficacy for non-neuropathic chronic pain is small. For diabetic peripheral neuropathy and post-herpetic neuralgia the evidence is stronger.
- Misuse and regulation. Several states have classified gabapentin as a controlled substance or added it to prescription monitoring programs. Compliance and surveillance burdens are applied unevenly and can affect Black patients' access to legitimate pain treatment.
Dosing: gabapentin is renally cleared. Because of 2021 eGFR recalculation, some Black patients previously considered to have normal kidney function are now correctly classified with CKD; gabapentin doses should be re-evaluated.
Common alternatives
Pregabalin (Lyrica) — similar mechanism, more predictable PK. Duloxetine — SNRI with FDA approval for neuropathic pain and fibromyalgia. Tricyclic antidepressants (amitriptyline, nortriptyline) — older but effective for neuropathic pain. Topical lidocaine or capsaicin for localized pain.
Side effects
- Sedation, dizziness
- Peripheral edema
- Weight gain
- Cognitive slowing
- Respiratory depression when combined with opioids — 2019 FDA warning
- Withdrawal with abrupt discontinuation
- Suicidality signal (FDA 2008)
Factors that affect adherence
Generic gabapentin is inexpensive. Dose titration (300 mg at night, then TID, then up) reduces early sedation and dizziness. Do not combine with opioids without explicit clinician guidance.
Questions to ask your doctor
Bring this list to your next appointment.
- Given that my pain [condition] has specific evidence for another drug, is gabapentin really the best first choice?
- Are my kidneys healthy enough for the dose we're using?
- Am I on any other drugs that could depress my breathing?
- How do we safely stop this if it doesn't work?
References
- Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938.
- Goodman CW, Brett AS. Gabapentinoids for pain: potential unintended consequences. N Engl J Med. 2019;381:104–106.
- U.S. Food and Drug Administration. FDA warns about serious breathing problems with gabapentin and pregabalin when used with opioids or in respiratory risk. 2019-12-19. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines
- U.S. Food and Drug Administration. Neurontin (gabapentin) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020235s041,020882s028,021129s027lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.